A B S T R A C T The d < 1.006 lipoproteins of patients in a kindred with atypical dysbetalipoproteinemia induced marked cholesteryl ester accumulation in mouse peritoneal macrophages. The affected family members had severe hypercholesterolemia and hypertriglyceridemia, xanthomatosis, premature vascular disease, the apo-E3/3 phenotype, and a predominance of cholesterol-rich f3-very low density lipoproteins (f,-VLDL) in the d < 1.006 fraction. When incubated with mouse peritoneal macrophages, the d < 1.006 lipoproteins or ,B-VLDL from the affected family members stimulated cholesteryl ['4C]oleate synthesis 15-to 30-fold above that caused by normal, control d < 1.006 lipoproteins (VLDL). The ability of the #l-VLDL to stimulate macrophage cholesteryl ester accumulation was greatly reduced as a consequence of treatment with hypolipidemic agents, which specifically reduced the concentration of ,3-VLDL. Two important differences were noted in a comparison of the f3-VLDL from these atypical dysbetalipoproteinemic subjects with that of classic E2/2 dysbetalipoproteinemics: (a) the f3-VLDL from the atypical subjects were severalfold more active in stimulating cholesteryl ester accumulation in macrophages, and (b) both the intestinal and hepatic 13-VLDL from the atypical subjects were active. The triglyceriderich, a2-migrating VLDL from the affected family members constituted <10% of the d < 1.006 fraction and were similar to normal VLDL in that they did not stimulate cholesteryl ester synthesis in the macrophages.
A B S T R A C T The d < 1.006 lipoproteins of patients in a kindred with atypical dysbetalipoproteinemia induced marked cholesteryl ester accumulation in mouse peritoneal macrophages. The affected family members had severe hypercholesterolemia and hypertriglyceridemia, xanthomatosis, premature vascular disease, the apo-E3/3 phenotype, and a predominance of cholesterol-rich f3-very low density lipoproteins (f,-VLDL) in the d < 1.006 fraction. When incubated with mouse peritoneal macrophages, the d < 1.006 lipoproteins or ,B-VLDL from the affected family members stimulated cholesteryl ['4C]oleate synthesis 15-to 30-fold above that caused by normal, control d < 1.006 lipoproteins (VLDL). The ability of the #l-VLDL to stimulate macrophage cholesteryl ester accumulation was greatly reduced as a consequence of treatment with hypolipidemic agents, which specifically reduced the concentration of ,3-VLDL. Two important differences were noted in a comparison of the f3-VLDL from these atypical dysbetalipoproteinemic subjects with that of classic E2/2 dysbetalipoproteinemics: (a) the f3-VLDL from the atypical subjects were severalfold more active in stimulating cholesteryl ester accumulation in macrophages, and (b) both the intestinal and hepatic 13-VLDL from the atypical subjects were active. The triglyceriderich, a2-migrating VLDL from the affected family members constituted <10% of the d < 1.006 fraction and were similar to normal VLDL in that they did not stimulate cholesteryl ester synthesis in the macrophages.
Received for publication 27 September 1982 and in revised form 6 April 1983.
Several lines of evidence indicate that the macrophage accumulation of cholesteryl esters was induced by a receptor-mediated uptake process and that the 3-VLDL were bound by a specific f3-VLDL receptor.
First, the uptake and degradation of the lipoproteins and the induction of cholesteryl ester formation displayed qualities of high affinity, saturable kinetics. Second, the uptake and degradation process was inhibited when the lysyl residues of the ,B-VLDL apoproteins were modified by reductive methylation. Third, the ,B-VLDL from the affected subjects competed with diet-induced canine '25I-f3-VLDL for the same cell surface receptors, but did not compete with chemically modified low density lipoproteins. Finally, the receptor-mediated uptake of these f3-VLDL resulted in lysosomal degradation of the lipoproteins, which could be prevented by incubating the cells with chloroquine. Normal, triglyceride-rich VLDL were also degraded when incubated with the macrophages, but they were not degraded by the same receptormediated process responsible for the degradation of the f3-VLDL of the patients. The degradation of the VLDL was not abolished by reductive methylation of the lipoproteins or by treatment of the cells with chloroquine. These studies demonstrate that the ,3-VLDL from subjects with atypical dysbetalipoproteinemia are taken up by macrophages via the same receptormediated process responsible for the uptake of dietinduced ,B-VLDL. The accelerated vascular disease seen in these patients may be the result of high con- centrations (6) , or preincubation with rabbit aortic endothelial cells (7) .
The first demonstration of naturally occurring lipoproteins causing cholesteryl ester accumulation in macrophages involved the incubation of mouse peritoneal macrophages with a subfraction of VLDL obtained from animals fed diets high in cholesterol and fat (8, 9 (10) .
The purpose of the present study was to investigate the interaction between macrophages and the ,B-VLDL of patients from a family with a newly described hyperlipidemic disorder. The affected members of this family were both hypercholesterolemic and hypertriglyceridemic; they also had high concentrations of f,-VLDL and premature atherosclerosis (11) . The subjects' lipoprotein abnormalities resembled those of patients with primary dysbetalipoproteinemia (type III hyperlipoproteinemia), although their lipoproteins did not have the classic apo E isoform pattern (i.e., E2/2) that is typical of primary dysbetalipoproteinemia (12, 13) . Instead, the affected family members appeared to be homozygous for an apo E isoform with the electrophoretic mobility of E3, or to be heterozygous for two isoforms with electrofocusing properties similar to ES (11) . High concentrations of ,B-VLDL that have a marked propensity to stimulate macrophage cholesteryl ester accumulation will be shown to constitute a second feature that distinguishes patients with this disorder from those with more classic dysbetalipoproteinemia. The reactivity of the classic dysbetalipoproteinemic patients' #-VLDL is less pronounced (14) .
METHODS
Human lipoproteins. All subjects (patients and controls) fasted for 12 h before a 500-ml plasmapheresis. The d < 1.006 fractions and LDL (d = 1.02-1.05) were isolated and washed as previously described (8) . The ,8-VLDL of the patients were isolated from the d < 1.006 fractions by GeonPevikon block electrophoresis (15) . Subfractionation of the ,B-VLDL by 4% agarose column chromatography was also performed as previously described (14) . Thef,-VLDL were radioiodinated with iodine-125 (III) (9) . More than 98% of the '251-radioactivity of the 125I-labeled s-VLDL was precipitated by 10% trichloracetic acid, and <2% of the 1251_ radioactivity was extracted into chloroform/methanol. Protein concentrations were determined by the Lowry method (16) . Polyacrylamide gel electrophoresis, using sodium dodecyl sulfate, was performed as described (17) .
Canine lipoproteins. The hyperlipidemic canine lipoproteins were isolated from foxhounds fed a semisynthetic, coconut oil-cholesterol diet for 2-6 mo as described (8) . The canine d < 1.006 fraction contained principally ,B-VLDL and was isolated by ultracentrifugation as described above for normal human VLDL.
Chemical modifications. Lysyl residues of the lipoproteins were modified by acetoacetylation with diketene or by reductive methylation as described (18) .
Cultured mouse macrophages. Mouse peritoneal mac-rophages were harvested from unstimulated mice using phosphate-buffered saline as described (5 Cellular cholesterol and cholesteryl ester mass. The mass of cellular cholesterol and cholesteryl esters was determined as described (21) , except that the initial extraction solvent contained 5 ,ug stigmasterol and 2.0 ;tg stigmasteryl oleate to serve as internal standards instead of [3H]cholesteryl oleate. The stigmasteryl oleate was synthesized essentially as described by Patel et al. (22) for the synthesis of cholesteryl esters. The samples were analyzed by gas-liquid chromatography (23 
RESULTS
The hyperlipidemic members of this kindred, ranging in age from 22 mo to 69 yr, had elevated concentrations of cholesteryl ester-enriched, d < 1.006 lipoproteins with ,B-electrophoretic mobility. The hyperlipidemia of the affected family members was expressed at an early age (evident at 22 mo of age), and the onset of xanthomas and atherosclerosis was also premature (11) . Lipid values (Table I) fractions (Table II) , despite the persistence of cholesterol-enriched ,B-VLDL in the plasma of these patients.
To validate this assay as an accurate indicator of cellular cholesteryl ester accumulation, an additional experiment was performed in which the d < 1.006 fraction from three of the affected subjects was incu- were responsible for inducing the greatest increases in macrophage cholesteryl ester accumulation (8, 9) . To determine whether the ,B-VLDL of these family members constituted the subfraction active in stimulating macrophage cholesteryl ester accumulation, the d < 1.006 lipoproteins of patient II-1 were subfractionated by Geon-Pevikon preparative electrophoresis into a2-and #-migrating subfractions (Table IV) fraction were fB-VLDL, as judged by paper electrophoresis. The f3-VLDL of patient II-1 were rich in cholesterol, and the cholesterol-to-protein ratio of the fB-VLDL was greater than that of the a2-VLDL (Table   TABLE III clearly resided wth the #l-VLDL, whereas the a2-VLDL were no more effective in stimulating cellular cholesteryl ester synthesis than the d < 1.006 fractions from control subjects ( Table V) . The i3-VLDL of affected family members could be further subfractionated into two subclasses (fl-VLDL-I and ,B-VLDL-II) by 4% agarose gel permeation chromatography (Table IV) . Data are shown for patient II-1, but similar results were obtained with analogous subfractions from patients III-2 and 111-4. The ,B-VLDL-I eluted in the void volume and contained lipoprotein particles with a mean diameter of 76 nm (±28 SD, n = 100), whereas the next fraction to elute, ,B-VLDL-II, contained smaller particles with a mean diameter of 42 nm (±13 SD, n = 100). The diameters (11) . It was of interest to determine whether the cellular uptake of the fB-VLDL from these patients was mediated by the same receptor as that described for f,-VLDL obtained from cholesterol-fed animals (8, 9) and classic primary dysbetalipoproteinemic subjects (14) , or whether the uptake was mediated by the receptor for chemically modified LDL, i.e., acetylated or acetoacetylated (AcAc) LDL. As shown in Fig. 2 , the nonradiolabeled f3-VLDL from both a cholesterolfed dog and patient III-2 (11) were identical in their ability to displace canine '251-f3-VLDL from binding to the macrophage f,-VLDL receptor, whereas human LDL were much less effective in competing with the '25I-#-VLDL. This suggested that the binding and uptake of the /B-VLDL from the affected subjects occurred via the same receptor responsible for canine f,-VLDL uptake by macrophages. It was also demonstrated that the f3-VLDL from affected family members could not competitively inhibit the binding and degradation of AcAc LDL by mouse peritoneal macrophages (data not shown). Moreover, the addition of fucoidin, previously shown to inhibit the binding of chemically modified LDL to the modified LDL binding site, inhibited both the binding and degradation of '25I-AcAc LDL (5, 9), but did not inhibit the receptor-mediated binding of the patients' j%-VLDL (data not shown). Thus, it appears that the uptake of /l-VLDL from these patients was mediated by a specific macrophage receptor for ,B-VLDL. The VLDL from control subjects did not appear to interact with this receptor and did not stimulate cholesteryl ester accumulation in macrophages.
Despite the inability of the control VLDL to stimulate cholesteryl ester accumulation (Fig. 3 A, C) , a significant amount of this a2-VLDL was degraded by the macrophages (Fig. 3 B, D) . As shown in Fig. 3 D, when the a2-VLDL of control subjects and the ,B-VLDL of affected subjects were added to dishes based on equal concentrations of cholesterol, there was equivalent degradation of the lipoproteins. To investigate further any possible role the fB-VLDL receptor might play in the uptake and degradation of normal VLDL, the lysyl residues of the apolipoproteins of a patient's p-VLDL and those of control VLDL were modified by reductive methylation. This modification has previously been shown to inhibit binding, uptake, and degradation of canine f#-VLDL by macrophages, indicating that the lysyl residues of the apolipoproteins are involved in the lipoprotein uptake mediated by the j3-VLDL receptor (25) . If receptor binding were a prerequisite for normal VLDL degradation, reductive methylation would inhibit binding and prevent any subsequent degradation of VLDL. As shown in Fig.  4 , reductive methylation of ,3-VLDL from an affected subject reduced ['4C]oleate incorporation in macrophage cholesteryl esters nearly to control levels. Furthermore, as shown in Fig. 5 , the reductive methylation of /3-VLDL from patient 111-2 reduced degradation of #l-VLDL by 83%. However, the same treatment had much less effect on the degradation of control VLDL.
Another indication of a difference in the mechanism by which normal VLDL and j3-VLDL are degraded was demonstrated by chloroquine treatment of macrophages (Fig. 5) . Chloroquine treatment of cells has been shown to inhibit the lysosomal degradation of lipoproteins that have entered the cell by means of receptor-mediated endocytosis (9, 26) . When mouse peritoneal macrophages were treated with chloroquine, the degradation of j3-VLDL decreased by 72%.
The effect of chloroquine in preventing the degradation of control VLDL was considerably less, implying that degradation did not depend on receptor-mediated endocytosis. The precise mechanism by which normal VLDL are degraded remains to be determined. The f3-VLDL from the patients with the atypical (E3/3 homozygous) dysbetalipoproteinemia differed from those previously described for classic (E2/2 homozygous) dysbetalipoproteinemics (14) . The ,B-VLDL from the atypical subjects were severalfold more active in stimulating cholesteryl ester accumulation in macrophages than the f3-VLDL of the more classic subjects (14) . Furthermore, unlike the fB-VLDL of classic dysbetalipoproteinemics (14) , both subfractions of the ,8-VLDL isolated by 4% agarose chromatography were active in stimulating cholesteryl ester formation in macrophages. Previously, it was shown that fraction I, apparently representing intestinal ,3-VLDL, was more active than fraction II, representing /8-VLDL of probable hepatic origin (14) . It is also unique for fl-VLDL and the hyperlipidemia to occur at such an early age (the youngest affected patient in this kindred was 22 mo of age at diagnosis) and for there to be vertical transmission through four generations. The nature of the determinant responsible for the uptake of j3-VLDL by macrophages remains in question. However, the present studies implicate a protein in mediating the uptake, since reductive methylation of lysyl residues abolishes the delivery of cholesterol to macrophages. The specific apoprotein involved has not been identified, but further characterization of the f#-VLDL from typical and atypical dysbetalipoproteinemic subjects will undoubtedly be helpful.
The role of receptor-mediated endocytosis in the uptake of the ,3-VLDL from the affected subjects was suggested by the following: (Fig. 4) and the degradation of '25I-#-VLDL (Fig. 5) ; and (c) chloroquine treatment of the macrophages, which inhibited the degradation of ,B-VLDL (Fig. 5) . It has been shown previously that reductive methylation prevents high affinity binding, uptake, and degradation of LDL and apo-E-enriched HDLC by the apo B,E receptor of fibroblasts (18) , and that the same modification of hyperlipidemic rabbit ,3-VLDL inhibits cholesteryl ester accumulation in macrophages (25) . The present studies confirm these observations and extend them to ,B-VLDL obtained from human subjects.
To determine whether the ,B-VLDL from the affected subjects were taken up by the same receptor that has been shown to bind canine f3-VLDL, further experiments were carried out. The displacement of canine 125I-,8-VLDL from macrophages by both nonradioiodinated canine ,B-VLDL and the ,B-VLDL of patient III-2 suggested that both lipoproteins were bound by the same receptor. Evidence that the uptake was not mediated by the receptor for chemically-modified LDL was obtained when the ,B-VLDL of the affected subjects failed to inhibit the uptake of 125I-AcAc LDL by macrophages.
Of considerable interest was the amount of degradation of normal a2-VLDL (Fig. 3 ) that occurred despite the lack of cellular cholesteryl ester accumulation stimulated by these lipoproteins. The relatively slight effect of reductive methylation on a2-VLDL degradation, compared with the effect of reductive methylation on ,B-VLDL degradation (Fig. 5) , suggests that the majority of the degradation of normal a2-VLDL is not mediated by the ,@-VLDL receptor. This inference was supported by data obtained from experiments involving chloroquine treatment of macrophages. The inhibition of lysosomal functioning by chloroquine treatment had little effect on macrophage degradation of a2-VLDL, whereas f,-VLDL degradation was markedly decreased. This indicates that the proteolysis of a2-VLDL may not be intralysosomal. Proteases may exist on the external cell surface of macrophages (27) , and it may be at these sites where most of the a2-VLDL degradation occurs. Alternatively, it has been proposed that apolipoprotein degradation by macrophages without concomitant cellular accumulation of cholesterol from the associated lipoprotein may be due to differences in the intracellular handling of cholesterol. Lipoproteins that gain entry to a cell via a specific lipoprotein receptor are degraded in lysosomes and stimulate cholesteryl ester synthesis, whereas nonreceptor-mediated uptake may allow apoprotein degradation but not a net increase in cellular cholesterol (28) .
The increase in cellular cholesteryl esters induced by the affected patients' VLDL was documented by two separate methods, which provided varied estimates of the extent of cholesteryl ester accumulation. The accumulation of cholesteryl esters in macrophages incubated with /l-VLDL suggests a possible mechanism for the development of accelerated atherogenesis (10, 29) . The fl-VLDL of cholesterol-fed animals (10, 29) and the f-VLDL of patients with classic dysbetalipoproteinemia (14) stimulate cholesteryl ester accumulation in these cells in vitro and are associated with accelerated atherosclerosis. Recently, it has been shown that lipid-laden foam cells grown from aortic explants of atherosclerotic rabbits possess a receptor for f3-VLDL, as well as having other characteristics of macrophages (3) . This evidence further supports the intriguing hypothesis that fl-VLDL and macrophages play a role in atherogenesis.
For reasons discussed above, the fi-VLDL of the patients with atypical dysbetalipoproteinemia appear to be more active in causing cholesteryl ester accumulation in macrophages than the #-VLDL described in subjects with classic dysbetalipoproteinemia (14) . The presence of these particles in the plasma at an early age may account for the relatively early onset of clinically evident atherosclerosis and xanthomas in these patients. It is significant that in the two patients treated with hypolipidemic agents, the plasma concentrations of fl-VLDL decreased, and furthermore, those fl-VLDL still present in the plasma lacked the ability to stimulate cholesteryl ester accumulation in macrophages (Tables I and II ). In addition, the treatment of these patients resulted in the resolution of their xanthomas (11) .
